Australia markets closed
  • ALL ORDS

    7,745.90
    -25.90 (-0.33%)
     
  • AUD/USD

    0.6897
    -0.0027 (-0.39%)
     
  • ASX 200

    7,539.00
    -19.10 (-0.25%)
     
  • OIL

    73.33
    -0.06 (-0.08%)
     
  • GOLD

    1,885.20
    +8.60 (+0.46%)
     
  • BTC-AUD

    33,115.06
    -1,005.79 (-2.95%)
     
  • CMC Crypto 200

    524.89
    -11.96 (-2.23%)
     

Regeneron Pharmaceuticals' (NASDAQ:REGN) three-year earnings growth trails the stellar shareholder returns

It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes to zero. But in contrast you can make much more than 100% if the company does well. For instance the Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) share price is 106% higher than it was three years ago. How nice for those who held the stock! On top of that, the share price is up 32% in about a quarter.

After a strong gain in the past week, it's worth seeing if longer term returns have been driven by improving fundamentals.

View our latest analysis for Regeneron Pharmaceuticals

To paraphrase Benjamin Graham: Over the short term the market is a voting machine, but over the long term it's a weighing machine. By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

Regeneron Pharmaceuticals was able to grow its EPS at 37% per year over three years, sending the share price higher. The average annual share price increase of 27% is actually lower than the EPS growth. So one could reasonably conclude that the market has cooled on the stock.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

earnings-per-share-growth
earnings-per-share-growth

We're pleased to report that the CEO is remunerated more modestly than most CEOs at similarly capitalized companies. It's always worth keeping an eye on CEO pay, but a more important question is whether the company will grow earnings throughout the years. Before buying or selling a stock, we always recommend a close examination of historic growth trends, available here..

A Different Perspective

It's nice to see that Regeneron Pharmaceuticals shareholders have received a total shareholder return of 21% over the last year. That's better than the annualised return of 15% over half a decade, implying that the company is doing better recently. Someone with an optimistic perspective could view the recent improvement in TSR as indicating that the business itself is getting better with time. It's always interesting to track share price performance over the longer term. But to understand Regeneron Pharmaceuticals better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Regeneron Pharmaceuticals , and understanding them should be part of your investment process.

But note: Regeneron Pharmaceuticals may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here